Patentable Molecule Derivates for Mental Health Therapies
Lighthouse is a European drug development company commencing pre-clinical trials for the development of novel patentable molecular derivates.
Lighthouse is developing psychedelic therapies aimed at addressing a number of pervasive mental health conditions.
Lighthouse is in the last stages of being able to produce pharmaceutical grade synthetic psylocibin for both research as well as for export.
Lighthouse will conduct research and produce synthetic psylocibin in a state of the art GLP approved lab, situated within a top university in Serbia. Additionally, Lighthouse is in the late stages for receiving a set of licenses in Montenegro to manufacture and export a wide range of psychedelic API’s at scale.
Lighthouse is led by experienced entrepreneurs working alongside top medical researchers to create transformative modalities addressing mental health conditions.